10) Transformational Medical Technologies Initiative
Abstract
Development of Platform Technologies: Invest in components necessary to develop an integrated capability from pathogen identification and characterization to countermeasure delivery. In particular, basic research is needed to develop animal models for diseases caused by BW agents. Such animal models are required to demonstrate drug effectiveness to generate the data required to file for licensure of BW drug countermeasures with the Food and Drug Administration (FDA). Efforts are also directed towards pathogen identification and characterization, using methods such as genetic sequencing to generate high-quality reference information. This data will be used in sophisticated analyses to delineate the exact nature of advanced or genetically engineered bio-threats.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2011
- Source ID
- 6fc3fd7cc6c9d735d4c879de7ed318b1